Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Tetraspanin in oncogenic epithelial-mesenchymal transition
Ruth J. Muschel, Annamaria Gal
Ruth J. Muschel, Annamaria Gal
Published March 20, 2008
Citation Information: J Clin Invest. 2008;118(4):1347-1350. https://doi.org/10.1172/JCI35308.
View: Text | PDF
Commentary

Tetraspanin in oncogenic epithelial-mesenchymal transition

  • Text
  • PDF
Abstract

Members of the L6 family of membrane proteins, a branch of the tetraspanin superfamily, are overexpressed in tumor cells from many types of cancers. However, direct evidence of their oncogenic activity has not been previously shown. In this issue of the JCI, Lee et al. demonstrate that overexpression of the tetraspanin superfamily member TM4SF5 in human hepatocellular carcinoma cells causes cellular phenotypic changes that resemble classical descriptions of epithelial-mesenchymal transition (EMT), with some unique aspects (see the related article beginning on page 1354). They also show that these TM4SF5-mediated effects trigger tumor formation when these cells are injected into mice. The study implicates TM4SF5, for the first time to our knowledge, in EMT oncogenic pathways of cancer progression.

Authors

Ruth J. Muschel, Annamaria Gal

×

Figure 1

Tetraspanin superfamily member TM4SF5 induces EMT and tumorigenesis.

Options: View larger image (or click on image) Download as PowerPoint
Tetraspanin superfamily member TM4SF5 induces EMT and tumorigenesis.
(A)...
(A) A monolayer of epithelial cells with polygonal morphology is held in formation by cell-cell contact between neighboring cells via molecules such as E-cadherin, as well as by the interaction of cell-surface integrins with proteins in the basement membrane. (B) In this issue of the JCI, Lee et al. (15) show that overexpression of TM4SF5 in human hepatocarcinoma SNU449 cells results in phenotypic changes in these cells that resemble EMT, such as an elongated morphology, loss of cell-cell contact, and loss of contact inhibition, resulting in overgrowth. (C) Lee et al. (15) provide data indicating that TM4SF5 overexpression enhances the expression and cytosolic stability of p27Kip1, likely via kinase interacting with stathmin– (KIS-) and/or Akt-mediated phosphorylation. This results in RhoA inhibition and subsequent changes in cell morphology resembling EMT. The authors observed decreased expression of ZO-1 and E-cadherin (the latter occurring in a Snail1-independent manner) and increased α-SMA expression. Loss of cell-cell contact leads to loss of contact inhibition between cells and uncontrolled multilayer growth. Importantly, this uncontrolled growth could be blocked by suppression of TM4SF5 or p27Kip1, Rho activation, or E-cadherin reexpression in these cells. Upon subcutaneous injection of TM4SF5-overexpressing SNU449 cells into nude mice, Lee et al. observed tumor formation. Figure modified from ref. 15.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts